Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 26, 2017
Pharmacy Choice - News - Generic Drugs - June 26, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 55     Next >>     Go To Page:

6/26/17 - AAM Biosimilars Council Praises Unanimous Supreme Court Ruling That Will Accelerate Patient Access to Biosimilar Medicines
By a News Reporter-Staff News Editor at Pharma Business Week The Association for Accessible Medicines applauded the U.S. Supreme Court's decision this week in Sandoz Inc. v. The Biosimilars Council, a division of the AAM, filed an amicus brief in the case consistent with the Court's ruling, recognizing delaying competition would cost patients, in
6/26/17 - Concordia International Corp. Announces RedHill Biopharma Has Started Promoting Donnatal in the U.S.
By a News Reporter-Staff News Editor at Pharma Business Week Concordia International Corp.- together with its subsidiaries, an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, announced that RedHill Biopharma Ltd., a specialty biopharmaceutical company, has started promoting Donnatal in...
6/26/17 - Inhalation and Nasal Spray Generic Drugs Market 2016-2023 Research Report
Globalinhalation and nasal spray generic drugs marketis analyzed on the basis of class and medical indication. Based on medical indication global inhalation and nasal spray generic drugs market is segmented as allergic rhinitis, a...
6/26/17 - Teva Announces Exclusive Launch of Generic Pataday in the United States
By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceutical Industries Ltd., announced the launch of generic Pataday 1 0.2%, in the U.S. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities,
6/26/17 - Teva Announces Launch of Generic Zetia in the United States
By a News Reporter-Staff News Editor at Clinical Trials Week Teva Pharmaceutical Industries Ltd., announced the launch of generic Zetia 1 tablets, 10 mg, in the U.S. "We are excited to add another strong generic to our U.S. portfolio and see potential to build on its success by leveraging our expertise in the cardiovascular area." With nearly
6/25/17 - 5 Top NASDAQ Biotech Stocks: AVEO Pharmaceuticals Gained 63.66 percent
The Investing News reported on a EY biotech market report that indicated despite the political turmoil, 2017 has been a good year for the industry and is poised to keep growing. Bluebird Bio released impressive data on genetic therapy treating inherited blood disorders. AVEO Pharmaceuticals BioDelivery Sciences Dynavax Technologies Catalyst...
6/25/17 - Jacobson Pharma Announces 2017 Annual Results
HONG KONG, Jun 25, 2017 Jacobson Pharma Corporation Limited, a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries for the year ended 31 March 2017. These annual results are the first since the co
6/24/17 - Bipartisan Group of Senators Urge FDA Commissioner to Address Prescription Drug Costs
Commissioner Gottlieb recently stated that the FDA will take measures to curb anticompetitive abuses of its regulatory process for the approval of generic drugs. In their letter, the senators advocate for their legislative solution and ask Commissioner Gottlieb to detail the regulatory actions the FDA can and cannot take to address strategies that.
6/24/17 - FDA rejects Pfizer`s Epogen biosimilar for the second time [Arab Finance (Egypt)]
This time around, an FDA complete response letter cited concerns about the same Pfizer fill-finish plant whose problems led the FDA to deny approval of a highly anticipated copy of Tevas Copaxone that was to be finished there. Pfizer late Thursday announced the FDA had issued the CRL for its proposed epoetin alfa biosimilar, a drug that has been on
6/24/17 - Genentechs subcutaneous rituximab approved in US [Sport360]
With cheaper biosimilars of the original Rituxan formulation edging closer to the US market, Genentechs owner Roche is looking for ways to maintain sales. Rituximab biosimilars have already been approved in Europe, where the subcutaneous formulation was approved last year. The FDA noted that the US label will include the following previously approv
6/24/17 - Sen. Grassley Joins Klobuchar, Bipartisan Group of Senate Judiciary Committee Members to Urge FDA Commissioner to Address Abuses in Regulatory Process That Delay Competition and Increase Prescription Drug Costs
Commissioner Gottlieb recently stated that the FDA will take measures to curb anticompetitive abuses of its regulatory process for the approval of generic drugs. In their letter, the senators advocate for their legislative solution and ask Commissioner Gottlieb to detail the regulatory actions the FDA can and cannot take to address strategies that.
6/24/17 - US FDA rejects Pfizer`s Epogen biosimilar citing McPherson site warning [T-break Tech (Middle East)]
Pfizer announced that epoetin alfa had been rejected yesterday, explaining the US Food and Drug Administration had issued a complete response letter related to matters noted in a Warning Letter issued on February 14, 2017. In addition, Pfizer made clear the FDA had not asked for additional clinical data, which is something that was requested when t
6/23/17 - Biogen's IMRALDI, an Adalimumab Biosimilar Candidate Referencing Humira, Granted Positive Opinion by Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for IMRALDI , an adalimumab biosimilar candidate referencing Humira . 1 The positive opinion will now be referred to the European Commission, which grants marketing authorization for medicines in the European Union. Today, the anti-
6/23/17 - Bipartisan Group of Members of Senate Judiciary Committee Urge FDA Commissioner to Address Abuses in Regulatory Process That Delay Competition, Increase Prescription Drug Costs
Commissioner Gottlieb recently stated that the FDA will take measures to curb anticompetitive abuses of its regulatory process for the approval of generic drugs. In their letter, the senators advocate for their legislative solution and ask Commissioner Gottlieb to detail the regulatory actions the FDA can and cannot take to address strategies that.
6/23/17 - Bipartisan Group of Senators Urge FDA Commissioner to Address Prescription Drug Costs
Commissioner Gottlieb recently stated that the FDA will take measures to curb anticompetitive abuses of its regulatory process for the approval of generic drugs. In their letter, the senators advocate for their legislative solution and ask Commissioner Gottlieb to detail the regulatory actions the FDA can and cannot take to address strategies that.
6/23/17 - Credence Research: Global Biosimilars Market Size Is Expected To Reach US$ 25.83 Bn By 2025 : Credence Research
The latest market report published by Credence Research, Ltd. "Global Biosimilars Market- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017- 2025," the Biosimilars market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83 Bn by 2025, expanding at a CAGR of 23.1% from 2017 to 2025.. Browse t
6/23/17 - Donald Trump Softens Stance on Drug Prices, Sends Biotech Stocks Soaring [Tehran Times (Iran)]
Donald Trump campaigned on reining in sky-high drug prices, and as recently as January, he said the industry was "getting away with murder." In the U.S., low-cost generic drugs represent nearly 90% of prescription-drug volume, yet high-cost specialty drugs used in indications such as cancer account for an increasingly larger share of total spending
6/23/17 - Dr. Reddy's Laboratories Announces the Launch of Bivalirudin for Injection in the U.S. Market
By a News Reporter-Staff News Editor at Drug Week Dr. Reddy's Laboratories Ltd. announced that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax for Injection, approved by the U.S. Food and Drug Administration. The Angiomax brand and generic had U.S. sales of approximately $198 mill
6/23/17 - Grassley Joins Klobuchar, Bipartisan Group of Senate Judiciary Committee Members to Urge FDA Commissioner to Address Abuses in the Regulatory Process...
Commissioner Gottlieb recently stated that the FDA will take measures to curb anticompetitive abuses of its regulatory process for the approval of generic drugs. In their letter, the senators advocate for their legislative solution and ask Commissioner Gottlieb to detail the regulatory actions the FDA can and cannot take to address strategies that.
6/23/17 - Jacobson Pharma Announces 2017 Annual Results
Jacobson Pharma Corporation Limited, a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries for the year ended 31 March 2017. These annual results are the first since the company's listing in Hong Ko
6/23/17 - Maine Senate passes Jackson's bill to lower drug costs
AUGUSTA, Maine- As the cost of prescription drugs continues to rise faster than wages and inflation alike, the Maine Senate on Thursday took action to lower drug costs by passing LD 1280, "An Act Regarding Drug Pricing," sponsored by Senate Democratic Leader Troy Jackson of Allagash. The FDA currently requires name-brand pharmaceutical producers to
6/23/17 - New Clopidogrel Therapy Study Findings Have Been Reported by Investigators at Eotvos Lorand University (Policy objective of generic medicines from...
New Clopidogrel Therapy Study Findings Have Been Reported by Investigators at Eotvos Lorand University. According to news originating from Budapest, Hungary, by NewsRx correspondents, research stated, "The objective of generic drug policies in most countries is defined from a disinvestment perspective: reduction in expenditures without compromising
6/23/17 - Study Findings from Metroplex Clinical Research Center Provide New Insights into Rheumatoid Arthritis (Efficacy and safety of the biosimilar ABP 501...
By a News Reporter-Staff News Editor at Drug Week Researchers detail new data in Autoimmune Diseases and Conditions- Rheumatoid Arthritis. According to news originating from Dallas, Texas, by NewsRx correspondents, research stated, "ABP 501 is a Food and Drug Administration- approved biosimilar to adalimumab; structural, functional and pharmacoki
6/22/17 - Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments
SUMMARY: The Food and Drug Administration is announcing the following meeting: "The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access." DATES: The meeting will be held on July 18, 2017, from 9 a.m. to 5 p.m. The deadline for submitting comments regarding this meeting is September 18, 2017. ADDRESSES: The meeting will be held
6/22/17 - Aiming for Amgen
The U.S. Supreme Court recently ruled that companies developing copies of these drugs, called biosimilars because exact generic copies can't be made, no longer must wait six months after getting regulatory approval to start selling them. Edward Jones analyst Ashtyn Evans says that will speed up competition for some Amgen medicines, which could redu
Articles(s): 1 - 25 of 55     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415